The evolution of platelet-directed pharmacotherapy.

Published

Journal Article (Review)

The evolution of platelet directed pharmacotherapy in the prevention and treatment of patients with thrombotic disorders is based soundly on a rapidly expanding knowledge of platelet biology. Traditionally viewed, throughout most of its relatively brief history in medicine, as an anucleate, passive contributor to hemostasis, a more contemporary perspective acknowledges platelets as complex, multidimensional cells that participate actively in coagulation, vascular repair, angiogenesis and thrombosis within the micro and the macro-circulatory systems. Herein, we consider platelet-directed pharmacotherapy from these fundamental, biology-based exemplars--megakaryocytes, signal transduction and the platelet--coagulation protease interface. We also highlight the emerging biopharmacology platform of oligonucleotide platelet adhesion antagonists and their complementary antidotes.

Full Text

Duke Authors

Cited Authors

  • Becker, RC; Smyth, S

Published Date

  • July 2009

Published In

Volume / Issue

  • 7 Suppl 1 /

Start / End Page

  • 266 - 271

PubMed ID

  • 19630814

Pubmed Central ID

  • 19630814

Electronic International Standard Serial Number (EISSN)

  • 1538-7836

Digital Object Identifier (DOI)

  • 10.1111/j.1538-7836.2009.03428.x

Language

  • eng

Conference Location

  • England